Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vivosim Lab Inc (VIVS)

Vivosim Lab Inc (VIVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,599
  • Shares Outstanding, K 2,608
  • Annual Sales, $ 140 K
  • Annual Income, $ -2,480 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 1.25
  • Price/Sales 29.34
  • Price/Cash Flow N/A
  • Price/Book 0.95

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +3.26%
on 03/30/26
2.2100 -35.52%
on 03/02/26
-0.7450 (-34.33%)
since 02/27/26
3-Month
1.3800 +3.26%
on 03/30/26
3.4000 -58.09%
on 01/30/26
-0.5850 (-29.10%)
since 12/26/25
52-Week
1.3800 +3.26%
on 03/30/26
5.3000 -73.11%
on 09/15/25
-0.9850 (-40.87%)
since 03/28/25

Most Recent Stories

More News
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 1.4250 (+3.26%)
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 1.4250 (+3.26%)
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 1.4250 (+3.26%)
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical...

VIVS : 1.4250 (+3.26%)
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing...

VIVS : 1.4250 (+3.26%)
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing...

VIVS : 1.4250 (+3.26%)
VivoSim: Fiscal Q1 Earnings Snapshot

VivoSim: Fiscal Q1 Earnings Snapshot

VIVS : 1.4250 (+3.26%)
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

VIVS : 1.4250 (+3.26%)
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

VIVS : 1.4250 (+3.26%)
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

VIVS : 1.4250 (+3.26%)
ONVO : 2.04 (+1.49%)

Business Summary

VivoSim Labs Inc. is a clinical-stage biotechnology company. It involved in developing drugs which are demonstrated to be effective in three-dimensional human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease. VivoSim...

See More

Key Turning Points

3rd Resistance Point 1.7133
2nd Resistance Point 1.6467
1st Resistance Point 1.5133
Last Price 1.4250
1st Support Level 1.3133
2nd Support Level 1.2467
3rd Support Level 1.1133

See More

52-Week High 5.3000
Fibonacci 61.8% 3.8026
Fibonacci 50% 3.3400
Fibonacci 38.2% 2.8774
Last Price 1.4250
52-Week Low 1.3800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.